VistaGen said that the NIH grant will support further development of patient-specific iPS cell programming processes by NuPotential, as well as VistaGen’s differentiation protocols and processes focused on the validation and use of the iPS cells for regenerative medicine applications and in clinically-relevant biological assays for small molecule drug discovery and drug rescue.
VistaGen CEO Shawn Singh said that the iPS cells produced through NuPotential’s safer reprogramming processes are expected to offer them many advantages in drug discovery and drug rescue applications of our Human Clinical Trials in a Test Tube platform.